Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice
- PMID: 36179690
- PMCID: PMC9671093
- DOI: 10.1016/j.immuni.2022.09.003
Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice
Abstract
Eliciting broadly neutralizing antibodies (bnAbs) is the core of HIV vaccine design. bnAbs specific to the V2-apex region of the HIV envelope acquire breadth and potency with modest somatic hypermutation, making them attractive vaccination targets. To evaluate Apex germline-targeting (ApexGT) vaccine candidates, we engineered knockin (KI) mouse models expressing the germline B cell receptor (BCR) of the bnAb PCT64. We found that high affinity of the ApexGT immunogen for PCT64-germline BCRs was necessary to specifically activate KI B cells at human physiological frequencies, recruit them to germinal centers, and select for mature bnAb mutations. Relative to protein, mRNA-encoded membrane-bound ApexGT immunization significantly increased activation and recruitment of PCT64 precursors to germinal centers and lowered their affinity threshold. We have thus developed additional models for HIV vaccine research, validated ApexGT immunogens for priming V2-apex bnAb precursors, and identified mRNA-LNP as a suitable approach to substantially improve the B cell response.
Keywords: B cell receptor; HIV vaccine; V2 apex; antibody; bnAbs; immunization; knockin; mRNA.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.R.W., K.M.M., J.M.S., and W.R.S. are named inventors on patent applications filed by Scripps and IAVI regarding ApexGT immunogens in this manuscript.
Figures
Similar articles
-
Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors.Immunity. 2022 Nov 8;55(11):2149-2167.e9. doi: 10.1016/j.immuni.2022.09.001. Epub 2022 Sep 29. Immunity. 2022. PMID: 36179689 Free PMC article.
-
A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.mBio. 2023 Feb 28;14(1):e0337022. doi: 10.1128/mbio.03370-22. Epub 2023 Jan 11. mBio. 2023. PMID: 36629414 Free PMC article.
-
Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies.J Int AIDS Soc. 2021 Nov;24 Suppl 7(Suppl 7):e25831. doi: 10.1002/jia2.25831. J Int AIDS Soc. 2021. PMID: 34806332 Free PMC article. Review.
-
A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.J Virol. 2020 Sep 15;94(19):e00814-20. doi: 10.1128/JVI.00814-20. Print 2020 Sep 15. J Virol. 2020. PMID: 32669335 Free PMC article.
-
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Immunol Rev. 2017 Jan;275(1):217-229. doi: 10.1111/imr.12501. Immunol Rev. 2017. PMID: 28133797 Free PMC article. Review.
Cited by
-
Rational optimization of glycoprotein E (gE)-encoding mRNA for improved Varicella-zoster virus mRNA vaccine development.Emerg Microbes Infect. 2024 Dec;13(1):2392661. doi: 10.1080/22221751.2024.2392661. Epub 2024 Sep 12. Emerg Microbes Infect. 2024. PMID: 39137287 Free PMC article.
-
mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies.Front Immunol. 2024 Jul 25;15:1426232. doi: 10.3389/fimmu.2024.1426232. eCollection 2024. Front Immunol. 2024. PMID: 39119336 Free PMC article.
-
mRNA-based HIV-1 vaccines.Clin Microbiol Rev. 2024 Sep 12;37(3):e0004124. doi: 10.1128/cmr.00041-24. Epub 2024 Jul 17. Clin Microbiol Rev. 2024. PMID: 39016564 Review.
-
Affinity gaps among B cells in germinal centers drive the selection of MPER precursors.Nat Immunol. 2024 Jun;25(6):1083-1096. doi: 10.1038/s41590-024-01844-7. Epub 2024 May 30. Nat Immunol. 2024. PMID: 38816616 Free PMC article.
-
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.NPJ Vaccines. 2024 Apr 6;9(1):74. doi: 10.1038/s41541-024-00862-8. NPJ Vaccines. 2024. PMID: 38582771 Free PMC article.
References
-
- Abbott R.K., Lee J.H., Menis S., Skog P., Rossi M., Ota T., Kulp D.W., Bhullar D., Kalyuzhniy O., Havenar-Daughton C., et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity. 2018;48:133–146. doi: 10.1016/j.immuni.2017.11.023. - DOI - PMC - PubMed
-
- Andrabi R., Voss J.E., Liang C.H., Briney B., McCoy L.E., Wu C.Y., Wong C.H., Poignard P., Burton D.R. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity. 2015;43:959–973. doi: 10.1016/j.immuni.2015.10.014. - DOI - PMC - PubMed
-
- Andrabi R., Su C.Y., Liang C.H., Shivatare S.S., Briney B., Voss J.E., Nawazi S.K., Wu C.Y., Wong C.H., Burton D.R. Glycans function as anchors for antibodies and help drive HIV broadly neutralizing antibody development. Immunity. 2017;47:524–537.e3. doi: 10.1016/j.immuni.2017.08.006. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous